2021 ASCO:肝细胞癌领域中国之声

2021-06-08 rayms MedSci原创

2021年6月4日,美国临床肿瘤学会(ASCO)年会正式拉开序幕。

202164日,全球肿瘤界的年度盛会——美国临床肿瘤学会(ASCO)年会正式拉开序幕。去年中国共有12项研究入选ASCO年会进行口头报告,创造历史。2021年再次见证奇迹,共有20项来自中国学者的研究获得2021 ASCO年会口头报告发言。梅斯医学为大家整理了不可切除/晚期肝细胞癌领域的中国重磅研究,分享给各位同道。

lenvatinb在不可切除的肝细胞癌患者临床实践中的剂量优化

Lenvatinib已成为不可切除肝细胞癌(u-HCC)患者的一线治疗药物。虽然8毫克或12毫克/天的Lenvatinib是标准起始剂量,但因剂量导致的不良事件发生率很高。在临床实践中,为了应对不良事件的发生,通常使用各种给药方案来减轻毒性。

来自上海复旦大学附属中山医院肝癌研究所研究团队,评估了在中国人群中lenvatinib的两种给药策略的安全性和抗肿瘤活性。结果揭示,通过剂量递增策略或可延长lenvatinib治疗期,与标准疗法相比,具有相当的疗效和更大的耐受性。

在这项研究中,研究人员纳入来自20184月至20197月间接受lenvatinib进行u-HCC治疗的患者。剂量递增策略如下:开始剂量为4mg/d,每两周递增一次(由于常见的不良事件是在用药后2周内发生),每次递增剂量为4mg。如果没有发生明显的药物相关的不良事件,最终达到8mg12mg。根据RECIST1.1标准,评估客观缓释率(ORR)和无进展生存期(PFS)。

结果显示,共纳入56名患者,其中剂量递增组为37名患者,标准剂量组为19名患者。剂量递增组的平均体重为64.79公斤,标准剂量组为58.76公斤。根据肝癌分期显示,BCLC C期比例分别为51.4%63.2%Child-pugh B期比例分别为16.2%5.3%

两组之间的基线人口统计学参数具有可比性(P> 0.05),ORR32.43vs 42.1%,P = 0.335),疾病控制率(86.4vs 84.2%,P = 0.686)和PFSP = 0.631)均无显著差异。同时,达到全剂量(按体重)的患者比例相似为48.6%和63.2%。标准剂量组的剂量减少率明显高于剂量递增组(36.8%vs 13.5%P=0.044)。另外,尽管两组之间3/4级不良事件并无显著性差异(P = 0.083),但标准剂量组的患者(36.8%7/19)比剂量递增组的患者(16.2%6/37)有更高的G3/4的发生率。

因此,Lenvatinib剂量递增策略可能是患者治疗期的替代疗法。未来需要更多的数据来证实剂量递增策略的长期疗效和安全性。

中国肝细胞癌(HCC)患者辅助治疗决策的影响因素

本研究旨在了解中国肝细胞癌(HCC)切除术后辅助治疗的患者决策因素。

该研究使用调查问卷(https://pro.wenjuan.com/t/jUZFU)对过去2年在中国27家医院接受HCC手术切除的患者进行了调查。问卷结果通过电话或网络收集反馈。

该问卷调查涵盖三个方面:辅助治疗的决策、治疗方案的选择和复发风险对接受辅助治疗意愿的影响,并对其从1(无影响)到7(高影响)进行评分。平均得分为67分的因素被认为是有影响的,分数≤5分的因素被认为不会产生影响。本研究得到了中山医院伦理委员会的批准,患者提供了知情同意书。

结果显示,总共收集了2220份有效答卷,2183名患者来自中山医院,37名来自其他26家医院,75%的受访者为男性,50-70岁的患者占比为60%50%患者家庭月收入≤5000元人民币(约740美元)。在受访者中,62%接受过辅助治疗,56%接受了系统治疗(化疗、酪氨酸激酶抑制剂、免疫治疗和中药),27%接受了经动脉化疗栓塞(TACE)加系统治疗,17%单独接受了TACE治疗。

大多数受访者(75%)认为医生是使用辅助治疗和选择治疗方案的决策者。在没有接受辅助治疗的38%的受访者中,90%的受访者表示医生建议不给予辅助治疗。当患者是决策者时,影响使用辅助治疗和选择治疗方案的因素从影响最多到最少排列依次为:疗效(预防肿瘤复发)、报销情况、治疗副作用和费用成本。患者接受辅助治疗的意愿受到预测复发风险的影响,在估计2年复发风险>10%>30%的受访者中,分别有40%56%的人认为他们应该接受辅助治疗。

因此,大多数患者接受了辅助治疗,其中最常见的是全身治疗和TACE。接受切除术的患者强烈希望通过辅助治疗减少术后复发。医生意见被认为是治疗决策中最重要的因素,其次是经济因素。当患者是决策者时,最具影响力的因素是治疗效果,其次是报销情况。

lenvatinib联合 TACE 治疗不可切除的肝细胞癌:中国真实世界证据的回顾性分析

TACElenvatinib被证明可以延长不可切除的HCC患者的总生存期,两者的联合同样可改善临床疗效,并在真实世界中得到了广泛使用。然而,在TACE基础上加用lenvatinb的最佳时机仍不清楚。该研究旨在评估两种联合策略治疗不可切除的肝细胞癌的疗效和安全性。

来自中国上海复旦大学中山医院肝癌研究所的研究人员收纳了来自201811月到20206月,79名患者接受了TACElenvatinib联合治疗,随访超过2个月,并被分为早期联合治疗组(在第一次TACE之前或后加用lenvatinib)和晚期联合治疗组(在至少两次TACE手术后加用lenvatinib)。根据RECIST1.1标准评估肿瘤反应和无进展生存期(PFS,从使用lenvatinib的第一天到病情进展或死亡的时间),在基线和每2个月后进行肝功能评估。

结果显示,最终共收纳48名不可切除 HCC患者,所有患者的中位随访时间为9.35.3-14.3)个月。两组患者的基线特征相似。早期联合组(n=22)和晚期联合组(n=26)的平均年龄分别为65±9.7岁和61±11.6岁;BCLC CHCC59%54%p=0.89);Child-Pugh A比例为81.8%77%p=0.73)。客观缓解率(ORR)(18.2% vs 26.9%P=0.51)和疾病控制率(90.9% vs 92.3%P=1.00)没有显著差异。早期联合治疗组的中位PFS明显长于晚期联合治疗组(14.5个月 vs 8.9个月;P=0.048)。两组的安全状况相似。3/4级不良事件分别为3例(13.6%)和2例(7.7%)(P=0.65)。

因此,该研究是迄今为止首个关于lenvatinibTACE联合治疗不可切除HCC患者时机的真实世界数据。对于具有较长mPFS的患者来说,早期联合治疗策略可能是一个更好的选择。

FOHAIC-1 研究:晚期肝细胞癌中对比肝动脉灌注化疗(HAIC)和索拉非尼治疗的疗效

中山大学肿瘤医院赵明教授牵头开展的FOHAIC-1研究旨在评估肝内肿瘤负荷较重的aHCC患者使用HAIC-FOLFOX方案作为一线治疗的效果,同时寻找获益相关的生物标志物。

这是一项开放标签的 3 期研究,入组的是未经系统治疗的晚期肝细胞癌患者,按照 1:1 的比例随机接受 FOLFOX 方案的肝动脉灌注化疗(HAIC)或者索拉非尼口服。入组患者的基线肝内肿瘤负荷较大,其中 80% 以上合并门静脉癌栓,中位肿瘤直径10 cm以上,肝内肿瘤负荷超过 50% 的患者达到了 40% 以上。

2017 5 月至 2020 5 月期间,共入组 260 例患者。主要终点方面,HAIC 组的 OS 显著优于索拉非尼组(中位 OS 分别为 13.9 月和 8.2 月,HR=0.408P<0.001)。HAIC 组有16例(12.3%)的患者实现了肿瘤降期,其中 15 例接受了根治性手术或射频治疗,这部分患者的中位 OS 20.8 月,1年生存率为 93.8%

仑伐替尼+ AK104 用于不可切除肝细胞癌的一线治疗

AK104是一种人源化IgG1双特异性抗体,能同时结合PD-1CTLA-4该项多中心、单臂、II期研究纳入30名无法切除的aHCC患者(93.3%HBV阳性),接受AK1046mg/kgq2w+仑伐替尼(标准剂量)作为一线治疗。

在目前可评估的18例患者中,疗效数据看起来很不错,RECIST v1.1 评价的 ORR 达到了44.4%DCR 77.8%。中位PFS未达到。安全性方面,3级及以上治疗相关不良事件的发生率为26.7%

目前,CTLA-4抗体的使用都是短时间使用之后停药,以减少不良事件的发生率,期待这类药物在国内早日上市。与之相对的是,个人对于双特异性抗体倒不是很期待,与其用固定组合的双特异性抗体,或许还不如自由地组合使用两种抗体。

RESCUE研究再更新,双艾方案喜获肝癌一、二线突破性中位OS数据!

本次ASCO年会,双艾组合在肝细胞癌领域共有5项研究进行数据公布及结果更新。其中徐建明教授牵头的卡瑞利珠单抗联合阿帕替尼治疗晚期肝细胞肝癌的RESCUE研究更新了总生存(OS)结果数据,一线治疗队列中位OS20.1个月,2OS率为43.3%,二线治疗队列中位OS21.8个月,2OS率为44.6%,展现了双艾方案对于晚期肝细胞癌(HCC)的获益。

中南大学湘雅医院龚连生教授团队亦对卡瑞利珠单抗联合阿帕替尼治疗不可切除肝细胞肝癌的临床结果与患者特征的相关性进行了回顾性分析,共纳入26例不可切除HCC患者,双艾组合的客观缓解率(ORR)57.7%,疾病控制率(DCR)84.62%,中位无进展生存期(PFS)11个月、中位OS18.2个月,该研究在真实世界中评估了卡瑞利珠单抗联合阿帕替尼治疗的疗效,但仍需更大样本量及更长期的随访来验证期结果。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1979141, encodeId=55df19e91418c, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Tue Aug 24 23:59:09 CST 2021, time=2021-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863573, encodeId=1c5a18635e310, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Tue Jan 11 01:59:09 CST 2022, time=2022-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939212, encodeId=f3da1939212ca, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Fri Feb 11 06:59:09 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972020, encodeId=fa0a9e2020f3, content=对晚期患者太可了, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff3c5417670, createdName=ms7000002042478470, createdTime=Tue Jun 08 23:14:55 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972015, encodeId=0ed69e201557, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJ42hR3zb89ZzkZVKorv74I6shMF3VlGLtBZczsr6uVSjeBF7ZAU2KLicPa2NekAOGfIglm1lDVwgA/132, createdBy=01945233793, createdName=杨三, createdTime=Tue Jun 08 22:46:36 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971984, encodeId=ecb19e198430, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9965517039, createdName=ms2000001251043087, createdTime=Tue Jun 08 21:52:02 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971959, encodeId=fa789e195961, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200529/3611e9bb629c4e5b81fbd8ce784b06cc/128487eae357460bb98f67d86230c218.jpg, createdBy=ab235268530, createdName=神盾医疗局局长Jack, createdTime=Tue Jun 08 20:34:59 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971874, encodeId=a8579e1874ee, content=好 , beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Tue Jun 08 16:17:43 CST 2021, time=2021-06-08, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1979141, encodeId=55df19e91418c, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Tue Aug 24 23:59:09 CST 2021, time=2021-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863573, encodeId=1c5a18635e310, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Tue Jan 11 01:59:09 CST 2022, time=2022-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939212, encodeId=f3da1939212ca, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Fri Feb 11 06:59:09 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972020, encodeId=fa0a9e2020f3, content=对晚期患者太可了, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff3c5417670, createdName=ms7000002042478470, createdTime=Tue Jun 08 23:14:55 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972015, encodeId=0ed69e201557, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJ42hR3zb89ZzkZVKorv74I6shMF3VlGLtBZczsr6uVSjeBF7ZAU2KLicPa2NekAOGfIglm1lDVwgA/132, createdBy=01945233793, createdName=杨三, createdTime=Tue Jun 08 22:46:36 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971984, encodeId=ecb19e198430, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9965517039, createdName=ms2000001251043087, createdTime=Tue Jun 08 21:52:02 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971959, encodeId=fa789e195961, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200529/3611e9bb629c4e5b81fbd8ce784b06cc/128487eae357460bb98f67d86230c218.jpg, createdBy=ab235268530, createdName=神盾医疗局局长Jack, createdTime=Tue Jun 08 20:34:59 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971874, encodeId=a8579e1874ee, content=好 , beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Tue Jun 08 16:17:43 CST 2021, time=2021-06-08, status=1, ipAttribution=)]
    2022-01-11 xjy02
  3. [GetPortalCommentsPageByObjectIdResponse(id=1979141, encodeId=55df19e91418c, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Tue Aug 24 23:59:09 CST 2021, time=2021-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863573, encodeId=1c5a18635e310, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Tue Jan 11 01:59:09 CST 2022, time=2022-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939212, encodeId=f3da1939212ca, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Fri Feb 11 06:59:09 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972020, encodeId=fa0a9e2020f3, content=对晚期患者太可了, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff3c5417670, createdName=ms7000002042478470, createdTime=Tue Jun 08 23:14:55 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972015, encodeId=0ed69e201557, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJ42hR3zb89ZzkZVKorv74I6shMF3VlGLtBZczsr6uVSjeBF7ZAU2KLicPa2NekAOGfIglm1lDVwgA/132, createdBy=01945233793, createdName=杨三, createdTime=Tue Jun 08 22:46:36 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971984, encodeId=ecb19e198430, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9965517039, createdName=ms2000001251043087, createdTime=Tue Jun 08 21:52:02 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971959, encodeId=fa789e195961, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200529/3611e9bb629c4e5b81fbd8ce784b06cc/128487eae357460bb98f67d86230c218.jpg, createdBy=ab235268530, createdName=神盾医疗局局长Jack, createdTime=Tue Jun 08 20:34:59 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971874, encodeId=a8579e1874ee, content=好 , beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Tue Jun 08 16:17:43 CST 2021, time=2021-06-08, status=1, ipAttribution=)]
    2022-02-11 quxin068
  4. [GetPortalCommentsPageByObjectIdResponse(id=1979141, encodeId=55df19e91418c, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Tue Aug 24 23:59:09 CST 2021, time=2021-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863573, encodeId=1c5a18635e310, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Tue Jan 11 01:59:09 CST 2022, time=2022-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939212, encodeId=f3da1939212ca, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Fri Feb 11 06:59:09 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972020, encodeId=fa0a9e2020f3, content=对晚期患者太可了, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff3c5417670, createdName=ms7000002042478470, createdTime=Tue Jun 08 23:14:55 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972015, encodeId=0ed69e201557, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJ42hR3zb89ZzkZVKorv74I6shMF3VlGLtBZczsr6uVSjeBF7ZAU2KLicPa2NekAOGfIglm1lDVwgA/132, createdBy=01945233793, createdName=杨三, createdTime=Tue Jun 08 22:46:36 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971984, encodeId=ecb19e198430, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9965517039, createdName=ms2000001251043087, createdTime=Tue Jun 08 21:52:02 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971959, encodeId=fa789e195961, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200529/3611e9bb629c4e5b81fbd8ce784b06cc/128487eae357460bb98f67d86230c218.jpg, createdBy=ab235268530, createdName=神盾医疗局局长Jack, createdTime=Tue Jun 08 20:34:59 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971874, encodeId=a8579e1874ee, content=好 , beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Tue Jun 08 16:17:43 CST 2021, time=2021-06-08, status=1, ipAttribution=)]
    2021-06-08 ms7000002042478470

    对晚期患者太可了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1979141, encodeId=55df19e91418c, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Tue Aug 24 23:59:09 CST 2021, time=2021-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863573, encodeId=1c5a18635e310, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Tue Jan 11 01:59:09 CST 2022, time=2022-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939212, encodeId=f3da1939212ca, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Fri Feb 11 06:59:09 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972020, encodeId=fa0a9e2020f3, content=对晚期患者太可了, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff3c5417670, createdName=ms7000002042478470, createdTime=Tue Jun 08 23:14:55 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972015, encodeId=0ed69e201557, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJ42hR3zb89ZzkZVKorv74I6shMF3VlGLtBZczsr6uVSjeBF7ZAU2KLicPa2NekAOGfIglm1lDVwgA/132, createdBy=01945233793, createdName=杨三, createdTime=Tue Jun 08 22:46:36 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971984, encodeId=ecb19e198430, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9965517039, createdName=ms2000001251043087, createdTime=Tue Jun 08 21:52:02 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971959, encodeId=fa789e195961, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200529/3611e9bb629c4e5b81fbd8ce784b06cc/128487eae357460bb98f67d86230c218.jpg, createdBy=ab235268530, createdName=神盾医疗局局长Jack, createdTime=Tue Jun 08 20:34:59 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971874, encodeId=a8579e1874ee, content=好 , beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Tue Jun 08 16:17:43 CST 2021, time=2021-06-08, status=1, ipAttribution=)]
    2021-06-08 杨三

    学习了

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1979141, encodeId=55df19e91418c, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Tue Aug 24 23:59:09 CST 2021, time=2021-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863573, encodeId=1c5a18635e310, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Tue Jan 11 01:59:09 CST 2022, time=2022-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939212, encodeId=f3da1939212ca, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Fri Feb 11 06:59:09 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972020, encodeId=fa0a9e2020f3, content=对晚期患者太可了, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff3c5417670, createdName=ms7000002042478470, createdTime=Tue Jun 08 23:14:55 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972015, encodeId=0ed69e201557, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJ42hR3zb89ZzkZVKorv74I6shMF3VlGLtBZczsr6uVSjeBF7ZAU2KLicPa2NekAOGfIglm1lDVwgA/132, createdBy=01945233793, createdName=杨三, createdTime=Tue Jun 08 22:46:36 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971984, encodeId=ecb19e198430, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9965517039, createdName=ms2000001251043087, createdTime=Tue Jun 08 21:52:02 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971959, encodeId=fa789e195961, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200529/3611e9bb629c4e5b81fbd8ce784b06cc/128487eae357460bb98f67d86230c218.jpg, createdBy=ab235268530, createdName=神盾医疗局局长Jack, createdTime=Tue Jun 08 20:34:59 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971874, encodeId=a8579e1874ee, content=好 , beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Tue Jun 08 16:17:43 CST 2021, time=2021-06-08, status=1, ipAttribution=)]
    2021-06-08 ms2000001251043087

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1979141, encodeId=55df19e91418c, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Tue Aug 24 23:59:09 CST 2021, time=2021-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863573, encodeId=1c5a18635e310, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Tue Jan 11 01:59:09 CST 2022, time=2022-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939212, encodeId=f3da1939212ca, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Fri Feb 11 06:59:09 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972020, encodeId=fa0a9e2020f3, content=对晚期患者太可了, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff3c5417670, createdName=ms7000002042478470, createdTime=Tue Jun 08 23:14:55 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972015, encodeId=0ed69e201557, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJ42hR3zb89ZzkZVKorv74I6shMF3VlGLtBZczsr6uVSjeBF7ZAU2KLicPa2NekAOGfIglm1lDVwgA/132, createdBy=01945233793, createdName=杨三, createdTime=Tue Jun 08 22:46:36 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971984, encodeId=ecb19e198430, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9965517039, createdName=ms2000001251043087, createdTime=Tue Jun 08 21:52:02 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971959, encodeId=fa789e195961, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200529/3611e9bb629c4e5b81fbd8ce784b06cc/128487eae357460bb98f67d86230c218.jpg, createdBy=ab235268530, createdName=神盾医疗局局长Jack, createdTime=Tue Jun 08 20:34:59 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971874, encodeId=a8579e1874ee, content=好 , beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Tue Jun 08 16:17:43 CST 2021, time=2021-06-08, status=1, ipAttribution=)]
    2021-06-08 神盾医疗局局长Jack

    不错

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1979141, encodeId=55df19e91418c, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Tue Aug 24 23:59:09 CST 2021, time=2021-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863573, encodeId=1c5a18635e310, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Tue Jan 11 01:59:09 CST 2022, time=2022-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939212, encodeId=f3da1939212ca, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Fri Feb 11 06:59:09 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972020, encodeId=fa0a9e2020f3, content=对晚期患者太可了, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff3c5417670, createdName=ms7000002042478470, createdTime=Tue Jun 08 23:14:55 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972015, encodeId=0ed69e201557, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJ42hR3zb89ZzkZVKorv74I6shMF3VlGLtBZczsr6uVSjeBF7ZAU2KLicPa2NekAOGfIglm1lDVwgA/132, createdBy=01945233793, createdName=杨三, createdTime=Tue Jun 08 22:46:36 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971984, encodeId=ecb19e198430, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9965517039, createdName=ms2000001251043087, createdTime=Tue Jun 08 21:52:02 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971959, encodeId=fa789e195961, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200529/3611e9bb629c4e5b81fbd8ce784b06cc/128487eae357460bb98f67d86230c218.jpg, createdBy=ab235268530, createdName=神盾医疗局局长Jack, createdTime=Tue Jun 08 20:34:59 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971874, encodeId=a8579e1874ee, content=好 , beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Tue Jun 08 16:17:43 CST 2021, time=2021-06-08, status=1, ipAttribution=)]
    2021-06-08 rayms

    0

相关资讯

JNCCN:诊断和治疗的延迟对肝细胞癌患者的影响

肝细胞癌(HCC)患者中诊断和治疗的延迟比较常见,但是治疗的延迟并不影响患者的预后。

Cancers:中性粒细胞/淋巴细胞比(NLR)是中期肝细胞癌(HCC)患者一线接受TACE治疗的预后指标。

中性粒细胞/淋巴细胞比(NLR)是中期肝细胞癌(HCC)患者一线接受TACE治疗的预后指标,并且高NLR提示较差的生存。

JNCI:近20年来肝癌的死亡率变化趋势

原发性肝癌的死亡率已开始降低~

Br J Cancer:特泊替尼tepotinib与索拉非尼sorafenib对晚期肝细胞癌患者的治疗对比

肝细胞癌(HCC)作为成人中最常见的原发性肝癌类型,其发生率随着慢性肝病发病率的升高而升高。

J Hepatology:索拉非尼能降低肝细胞癌的肿瘤生长速度降低和肝功能的恶化

肝细胞癌 (HCC) 是全球最常见的原发性肝癌类型,也是第三大癌症死亡相关的原因,每年有超过 500000 人受到此疾病的影响。

Int J Cancer:意外发现:AGEs摄入量与肝癌风险呈负相关!

与预期相反,在一项大型跨国队列研究中,较高的晚期糖基化终末产物(AGEs)膳食摄入量,包括来自油炸、烤制或烤制食品中的AGEs,与肝细胞癌(HCC)风险下降相关。